Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Metabolic Diseases

Background:

• Sodium-glucose cotransporter-2 (SGLT2) inhibitors are primarily used for type 2 diabetes mellitus.
• Clinical trials revealed unexpected benefits of SGLT2 inhibitors in heart failure patients.
• This review examines the broader cardiovascular and skeletal impacts of SGLT2 inhibitors.

Purpose of the Study:

• To explore the effects of SGLT2 inhibitors on cardiovascular disease beyond heart failure.
• To investigate the impact of SGLT2 inhibitors on skeletal health.
• To synthesize current findings on SGLT2 inhibitors' influence on lipid metabolism and related conditions.

Main Methods:

• Review of clinical trials and preclinical studies on SGLT2 inhibitors.
• Analysis of data on lipid profiles, cardiac function, and tissue lipid accumulation.
• Examination of studies investigating effects on atherosclerosis, vascular calcification, and bone health.

Main Results:

• SGLT2 inhibitors show variable effects on serum lipids (free fatty acids, triglycerides, cholesterol) and cardiac function.
• Consistent reduction in lipid accumulation in the liver, kidney, and heart observed.
• Sex-dependent effects noted: reduced atherosclerosis and aortic calcification in male mice, but not female.
• Conflicting data exists regarding SGLT2 inhibitors' impact on fracture and amputation risks.

Conclusions:

• SGLT2 inhibitors demonstrably reduce tissue lipid accumulation.
• Atherosclerosis and vascular calcification are reduced in a sex-dependent manner.
• The precise effects on overall lipid levels and bone health require further clarification.